No Data
No Data
Protalix Biotherapeutics Gains Momentum in the Rare Disease Space: Analysts | NYSE-A:PLX
Protalix BioTherapeutics to Participate in the 2025 BIO CEO & Investor Conference
Protalix BioTherapeutics Analyst Ratings
H.C. Wainwright Maintains Protalix Biotherapeutics(PLX.US) With Buy Rating, Raises Target Price to $15
Protalix BioTherapeutics Outlines Strategic Roadmap for 2025 | NYSE:PLX
NYSE American New 52-Week Highs And Lows
Unlock the Full List